Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

InBios, UN-Reno Partner to Develop Diagnostic for Melioidosis

by Global Biodefense Staff
August 9, 2012

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a grant to researchers at the University of Nevada, Reno and their collaborator, InBios International of Seattle, to further development of a rapid diagnostic for melioidosis.

Also known as Whitmore’s disease, melioidosis is a difficult to treat infection caused by Burkholderia pseudomallei, a Category B biothreat as classified by the Centers for Disease Control and Prevention.

Melioidosis is predominately a disease of tropical climates, especially in Southeast Asia and northern Australia where it is widespread. The B. pseudomallei bacteria causing melioidosis are found in contaminated water and soil. It is spread to humans and animals through direct contact with the contaminated source, is easily aerosolized and has a high mortality rate.

With NIAID’s two-year Phase I Small Business Technology Transfer (STTR) grant, the recipients will further development of their Active Melioidosis Detect (AMD) test.

“Results so far are very encouraging,” said David AuCoin, Principle Investigator at the Diagnostics Discovery Laboratory, University of Nevada School of Medicine. “We have a prototype of the product in Thailand and Australia now, regions that are hardest hit, to evaluate its effectiveness in endemic settings.”

Currently, there are no validated diagnostic products for melioidosis, and patient samples must be cultured, taking three to seven days to diagnose the disease. “Unfortunately, melioidosis can kill you well before the diagnosis is confirmed,” said AuCoin.

AuCoin produced and has been working with the monoclonal antibody used in the test since 2009. The work is also partially funded by the Pacific Southwest Regional Center for Excellence in Biodefense and Emerging Infections.

The team is working to secure Phase II funding following the two years of Phase I work, which will allow another three years of product development to generate the necessary preclinical studies to submit an application to the FDA for approval to distribute the assay.

Source: UN-Reno

Tags: AwardsBurkholderia

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC